Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent

Patent metadata

Field	Value
Publication number	US-11478440-B2
Application number	US-201816606233-A
Country	US
Kind code	B2
Filing date	Apr 18, 2018
Priority date	Apr 18, 2017
Publication date	Oct 25, 2022
Grant date	Oct 25, 2022

Abstract

The present invention relates to a combination product and its use in therapy.

First claim

The invention claimed is:

1. A method of delaying, reversing or slowing the progression of a disease, comprising administering to a subject in need of treatment a therapeutically effective amount of a combination product, said combination product comprises:
(i) elafibranor, a pharmaceutically acceptable salt or a solvate thereof;
and
(ii) an anti-NASH, anti-fibrotic or anti-cholestatic agent selected from the group consisting of Selonsertib, GKT-831, PXS-4728A, Aramchol, PBI-4050, MSDC-0602k, VK-2809, MGL-3196, Vismodegib, CF-102 (Namodenoson), MT-3995 (Apararenone), JKB-121 (Nalmefene), emricasan, KD-025, and DUR-928 or a pharmaceutically acceptable salt thereof;
wherein said disease is selected from the group consisting of liver fibrosis, liver cirrhosis, metabolic liver diseases, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), drug-induced liver diseases, alcohol-induced liver diseases, infectious agent induced liver diseases, inflammatory liver diseases, immune system dysfunction-mediated liver diseases, dyslipidemia, cardiovascular diseases, restenosis, syndrome X, metabolic syndrome, diabetes, obesity, hypertension, chronic cholangiopathies, Primary Sclerosing Cholangitis (PSC), Primary Biliary Cholangitis (PBC), biliary atresia, progressive familial intrahepatic cholestasis type 3 (PFIC3), inflammatory bowel diseases, Crohn's disease, ulcerative colitis, liver cancer, hepatocallular carcinoma, gastrointestinal cancer, gastric cancer, colorectal cancer, metabolic disease-induced liver fibrosis or cirrhosis, NAFLD-induced fibrosis or cirrhosis, NASH-induced fibrosis or cirrhosis, alcohol-induced liver fibrosis or cirrhosis, drug-induced liver fibrosis or cirrhosis, infectious agent-induced liver fibrosis or cirrhosis, parasite infection-induced liver fibrosis or cirrhosis, bacterial infection-induced liver fibrosis or cirrhosis, viral infection-induced fibrosis or cirrhosis, HBV-infection induced liver fibrosis or cirrhosis, HCV-infection induced liver fibrosis or cirrhosis, HIV-infection induced liver fibrosis or cirrhosis, dual HCV and HIV-infection induced liver fibrosis or cirrhosis, radiation- or chemotherapy-induced fibrosis or cirrhosis, biliary tract fibrosis, liver fibrosis or cirrhosis due to any chronic cholestatic disease, gut fibrosis of any etiology, Crohn's disease-induced fibrosis, ulcerative colitis-induced fibrosis, small intestine fibrosis, colon fibrosis, stomach fibrosis, lung fibrosis, lung fibrosis consecutive to chronic inflammatory airway diseases, chronic obstructive pulmonary disease (COPD), asthma, emphysema, smoker's lung, tuberculosis, pulmonary fibrosis, and idiopathic pulmonary fibrosis (IPF).

2. The method according to claim 1 , wherein component (i) is elafibranor.

3. The method according to claim 1 , wherein said combination product does not contain cenicriviroc (CVC) or obeticholic acid (OCA).

Assignees

• Genfit

Inventors

• Walczak Robert
• Belanger Carole
• Legry Vanessa
• Noel Benoît
• Descamps Emeline
• Vidal Guillaume
• Walczak Mathilde

Classifications

• A61K31/435

  having six-membered rings with one nitrogen as the only ring hetero atom · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K31/194

  having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid · CPC title